English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
DATE OF BOARD MEETING
2024-03-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-03-05
Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-06
Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-02-06
VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035
2024-01-25
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-01-04
EXTENSION OF WAIVER REGARDING THE QUALIFICATION AND EXPERIENCE OF A JOINT COMPANY SECRETARY
2023-12-19
VOLUNTARY ANNOUNCEMENT - A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA
2023-12-08
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF RESEARCH UPDATES ON KN026 AT THE SABCS 2023
2023-12-07
1
2
3
4
PREV
1/21
NEXT